LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community.

“We are excited to welcome Dr. Zaki to ADC Therapeutics and look forward to his leadership of the development of our deep pipeline of antibody drug conjugates,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “We sincerely thank Dr. Camardo for his tireless commitment to ADC Therapeutics and people living with cancer around the world.”

Dr. Zaki has spent over 20 years in oncology and hematology drug development. Most recently, he served as Vice President & Global Head of Oncology Development at AbbVie. Prior to AbbVie he spent 9 years at Celgene. Previously, Dr. Zaki worked at Sanofi-Aventis and Centocor, Inc., a subsidiary of Johnson & Johnson. He earned his MD and MS at Ain Shams University School of Medicine in Cairo, Egypt and his PhD from the University of Pennsylvania and Ain Shams University School of Medicine in a joint degree program. Dr. Zaki also served on the faculty of both institutions and was a practicing physician earlier in his career.

“ADC Therapeutics is a pioneer and leader in the evolving field of antibody drug conjugates,” said Dr. Zaki. “I look forward to working with the Company’s experienced team of researchers to expand on their innovative science and bring more therapeutic options to those impacted by cancer worldwide.”

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.